Pharmatching Portrays Biosimilars

Pharmatching Portrays Biosimilars

Due to the complex nature of biosimilars, pharma manufacturers need to rely, partly or to a large extent, on external capacities and expertise. The more classically generic the company’s background, the more this holds true. In this issue of Pharmatching Portrays, we showcase some of the Specialist Providers that have stepped in to meet this demand.

Pharma IQ spoke to Dr. Gabriele Dallmann, CEO of about biosimilar and the guidelines, players and providers in the sector.

Download this piece to learn more about:

  • The challenges of biosimilar monoclonal antibodies
  • The players and their responsibilities within the sector
  • Regulatory guidance at a glance

Please note: That all fields marked with an asterisk (*) are required.